NeuroPace Inc (NPCE) Stock Analysis and Metrics

NeuroPace

NASDAQ: NPCE

$14.80 ▲ +0.12 (+0.82%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap494.96 Mn

P/E-9.38

P/S4.97

Div. Yield0.00

Total Debt (Qtr)59.02 Mn

Revenue Growth (1y) (Qtr)-2.02

Add ratio to table…

About

NeuroPace, Inc. is a medical device company focused on developing and commercializing responsive neurostimulation therapies for patients with drug resistant epilepsy. The company’s flagship product, the RNS System, is a brain responsive neurostimulation device that continuously monitors intracranial electroencephalogram activity, detects patient specific abnormal patterns, and delivers targeted electrical stimulation to prevent seizures. NeuroPace’s RNS System is the first and only FDA approved closed loop system that both provides therapy and records brain data for clinician review. As of December 31, 2024, more than 6,000 patients had received the RNS System, and the company estimates that approximately 575,000 adults in the United States suffer from drug resistant focal epilepsy, representing a total addressable market of about $27 billion. The company operates within the neurological devices sector of the healthcare industry, aiming to reduce seizure frequency and improve quality of life for a patient population that has limited response to antiepileptic drugs.

NeuroPace generates revenue principally from the sale of its RNS System neurostimulator, cortical and depth leads, and related accessories to hospitals and epilepsy centers that perform implant procedures. In addition to the initial system sale, the company earns recurring revenue from the replacement neurostimulator, which is required approximately every eleven years when the device’s battery reaches end of life. NeuroPace also benefits from the reimbursement environment surrounding its product, as hospitals and physicians receive payment for implantation, intraoperative programming, and follow up services such as periodic in person or remote review of the recorded brain activity data. The company’s sales are conducted primarily through a direct sales force in the United States, targeting epileptologists who prescribe the system and neurosurgeons who implant it, with substantially all revenue derived from domestic markets.

NeuroPace occupies a differentiated niche in the epilepsy neuromodulation market, where its RNS System is the only FDA approved device that combines responsive stimulation with continuous intracranial electroencephalogram monitoring and data storage. The principal competitors in this space are LivaNova plc, which markets the vagus nerve stimulation system, and Medtronic plc, which markets the deep brain stimulation system for epilepsy. Unlike those continuous stimulation technologies, the RNS System delivers therapy only when abnormal brain activity is detected, resulting in an average of about three minutes of stimulation per day and a lower incidence of stimulation related side effects such as memory impairment or mood changes. NeuroPace’s competitive advantage is further reinforced by its proprietary data platform, which aggregates more than 19,000,000 intracranial electroencephalogram records from over 6,000 implanted patients and enables clinicians to optimize therapy settings over time, thereby improving clinical outcomes. The company also benefits from established reimbursement for implantation, programming, and data review services, a feature not available for competing neuromodulation devices.

NeuroPace’s customers consist of hospitals and specialized epilepsy centers that have the capability to perform intracranial implantation of the neurostimulator, particularly the approximately 200 Level 4 comprehensive epilepsy centers in the United States. Within these centers, epileptologists serve as the prescribing physicians who identify appropriate patients and determine therapy parameters, while neurosurgeons carry out the surgical implantation of the leads and neurostimulator. The company also works with a growing network of epileptologists and functional neurosurgeons practicing outside of Level 4 centers following the 2023 PMA supplement approval that expanded prescribing rights to about 1,800 additional clinicians. Ultimately, the end users of the technology are patients diagnosed with drug resistant focal epilepsy who receive the implanted system and benefit from ongoing seizure reduction and improved quality of life.

Investment Thesis

▲ Bull case

NeuroPace (NPCE) is positioned for accelerated revenue growth driven by the maturation of its commercial investments and the early-stage replacement cycle of its RNS system, which is expected to become a more meaningful revenue stream starting in 2027 and beyond. The company reported less than 5% of revenue and below 10% of volume from RNS replacements in Q1 FY26, indicating the replacement cycle is in its initial phase, but management emphasized that this will gain significance as the installed base ages, with the nominal 11-year battery life of the RNS-320 device creating a predictable, recurring revenue opportunity. This dynamic is underappreciated by the market, which focuses primarily on new implant growth while overlooking the long-term annuity-like potential of device replacements, which will contribute to both revenue stability and gross margin expansion over time as replacement procedures scale with minimal incremental cost due to lead reuse. The company’s guidance already assumes 21%-23% RNS revenue growth for FY26, and the replacement cycle represents a structural tailwind that could sustain or even accelerate growth beyond current expectations, particularly as NeuroPace continues to expand its active prescriber base and patient pipeline to all-time highs, signaling durable demand generation across Level 4 epilepsy centers and community referral networks.
The FDA approval of ECoG Assistant represents a significant, under-leveraged catalyst that enhances NeuroPace’s competitive moat through AI-driven workflow efficiency, which directly addresses a key barrier to broader adoption—clinician burden in reviewing intracranial EEG (iEEG) data. Built on 124,450 epileptologist-labeled iEEG records from the world’s only long-term intracranial EEG dataset linked to therapy and outcomes, ECoG Assistant enables faster, more confident treatment decisions by identifying electrographic seizure activity and revealing timing patterns and potential triggers. This tool lowers the barrier for new physician adoption while deepening engagement among high-utilizing centers by improving efficiency, allowing clinicians to manage more RNS patients without increasing headcount. The approval, coupled with the ongoing development of a multimodal foundational AI model trained on over 8,000 implants and 26 million iEEG recordings, positions NeuroPace to lead the industry in data-guided neuromodulation—a structural shift that could redefine standard of care in epilepsy treatment. The market is underestimating how this proprietary data advantage, combined with AI innovation, will drive differentiation, pricing power, and long-term platform defensibility against competitors lacking comparable longitudinal data assets.
NeuroPace’s 2026 revenue guidance increase to $99 million–$101 million (up from $98 million–$100 million) reflects improved visibility into both core RNS growth and service revenue, with approximately $500 thousand of the increase attributable to newly predictable service revenue from data collaborations, including a new partnership. This signals a strategic shift toward monetizing its unique iEEG data asset beyond hardware sales, creating a higher-margin, recurring revenue stream that is less cyclical than procedure-dependent implant sales. The company explicitly noted that expanded service revenue visibility now supports including this figure in guidance, indicating management’s growing confidence in the scalability and predictability of this business line. As service revenue scales, it will contribute to operating leverage and margin expansion, particularly as R&D and SG&A expenses grow at a slower pace than revenue—evidenced by Q1 FY26 operating expenses rising only 10% despite 20% revenue growth ex-DIXI. The market is overlooking this evolution from a pure-play device company to a data-enabled neuromodulation platform, which could significantly enhance long-term valuation multiples as investors re-rate NeuroPace for its software and AI-driven services.

NeuroPace (NPCE) is positioned for accelerated revenue growth driven by the maturation of its commercial investments and the early-stage replacement cycle of its RNS system, which is expected to become a more meaningful revenue stream starting in 2027 and beyond. The company reported less than 5% of revenue and below 10% of volume from RNS replacements in Q1 FY26, indicating the replacement cycle is in its initial phase, but management emphasized that this will gain significance as the installed base ages, with the nominal 11-year battery life of the RNS-320 device creating a predictable, recurring revenue opportunity. This dynamic is underappreciated by the market, which focuses primarily on new implant growth while overlooking the long-term annuity-like potential of device replacements, which will contribute to both revenue stability and gross margin expansion over time as replacement procedures scale with minimal incremental cost due to lead reuse. The company’s guidance already assumes 21%-23% RNS revenue growth for FY26, and the replacement cycle represents a structural tailwind that could sustain or even accelerate growth beyond current expectations, particularly as NeuroPace continues to expand its active prescriber base and patient pipeline to all-time highs, signaling durable demand generation across Level 4 epilepsy centers and community referral networks.
The FDA approval of ECoG Assistant represents a significant, under-leveraged catalyst that enhances NeuroPace’s competitive moat through AI-driven workflow efficiency, which directly addresses a key barrier to broader adoption—clinician burden in reviewing intracranial EEG (iEEG) data. Built on 124,450 epileptologist-labeled iEEG records from the world’s only long-term intracranial EEG dataset linked to therapy and outcomes, ECoG Assistant enables faster, more confident treatment decisions by identifying electrographic seizure activity and revealing timing patterns and potential triggers. This tool lowers the barrier for new physician adoption while deepening engagement among high-utilizing centers by improving efficiency, allowing clinicians to manage more RNS patients without increasing headcount. The approval, coupled with the ongoing development of a multimodal foundational AI model trained on over 8,000 implants and 26 million iEEG recordings, positions NeuroPace to lead the industry in data-guided neuromodulation—a structural shift that could redefine standard of care in epilepsy treatment. The market is underestimating how this proprietary data advantage, combined with AI innovation, will drive differentiation, pricing power, and long-term platform defensibility against competitors lacking comparable longitudinal data assets.
NeuroPace’s 2026 revenue guidance increase to $99 million–$101 million (up from $98 million–$100 million) reflects improved visibility into both core RNS growth and service revenue, with approximately $500 thousand of the increase attributable to newly predictable service revenue from data collaborations, including a new partnership. This signals a strategic shift toward monetizing its unique iEEG data asset beyond hardware sales, creating a higher-margin, recurring revenue stream that is less cyclical than procedure-dependent implant sales. The company explicitly noted that expanded service revenue visibility now supports including this figure in guidance, indicating management’s growing confidence in the scalability and predictability of this business line. As service revenue scales, it will contribute to operating leverage and margin expansion, particularly as R&D and SG&A expenses grow at a slower pace than revenue—evidenced by Q1 FY26 operating expenses rising only 10% despite 20% revenue growth ex-DIXI. The market is overlooking this evolution from a pure-play device company to a data-enabled neuromodulation platform, which could significantly enhance long-term valuation multiples as investors re-rate NeuroPace for its software and AI-driven services.

▼ Bear case

NeuroPace (NPCE) faces significant near-term execution risk in its pursuit of idiopathic generalized epilepsy (IGE) indication expansion, as the FDA’s 180-day PMA review clock pause for the Nautilus supplement—triggered by follow-up questions during the mid-cycle review—introduces uncertainty regarding both timing and the potential label restrictions that may limit commercial uptake. While management anticipates a midyear determination, the agency’s focus on clarifying data interpretation and context around analyses, rather than just accepting the submitted evidence, suggests scrutiny over the robustness of the NAUTILUS trial’s primary endpoint, which did not meet statistical significance despite strong secondary outcomes like a 77% median reduction in generalized tonic-clonic seizures. This regulatory hesitation could delay approval beyond midyear, compress the revenue contribution window for FY26, and necessitate additional data generation or labeling concessions that reduce the addressable patient population or increase commercialization costs, undermining the bullish case for IGE-driven upside that is currently excluded from guidance but widely anticipated by investors.
The company’s operating leverage remains fragile and contingent on sustained commercial execution, as evidenced by Q1 FY26 non-GAAP operating expenses increasing 10% year-over-year to $21.5 million—driven by higher sales and marketing ($11.0 million, up from $9.6 million) and general and administrative costs ($4.0 million, up from $3.3 million)—while R&D spending declined only slightly ($6.5 million vs. $6.6 million), indicating limited efficiency gains in core innovation spend. Although operating expense growth stayed below the 20% revenue growth ex-DIXI, this leverage is dependent on continued productivity from recent commercial team investments, including sales representative additions and nurse navigator team expansion, which may not yield proportional returns if prescriber adoption or patient pipeline velocity fails to accelerate as expected. The reliance on these investments to drive growth introduces execution risk, particularly if macroeconomic headwinds or healthcare budget constraints slow capital allocation at Level 4 centers or delay community referral maturation, potentially undermining the assumed 21%-23% RNS growth trajectory and delaying profitability milestones.
Reimbursement dynamics for the RNS system present a structural challenge that could constrain long-term margin expansion and adoption rates, despite recent positive OPPS and APC mapping updates for device replacement. While management highlighted improved reimbursement alignment for replacements as a future tailwind, the first-time implant procedure remains on Medicare’s inpatient-only list, creating a significant barrier to outpatient adoption and limiting site-of-service flexibility, which is increasingly valued by hospitals and clinicians seeking to reduce costs and improve patient throughput. The lack of outpatient reimbursement for new implants constrains the total addressable market, particularly in community hospitals and ambulatory surgery centers, and may slow penetration beyond Level 4 epilepsy centers—a critical factor given management’s emphasis on community relationships as durable referral channels. Although NeuroPace advocates for policy change and cites broader payer openness to neuromodulation value, the absence of a clear pathway to outpatient APC status for first-time implants introduces uncertainty around scalability and could result in slower-than-expected utilization growth, especially if cost-containment pressures intensify in the U.S. healthcare system.

NeuroPace (NPCE) faces significant near-term execution risk in its pursuit of idiopathic generalized epilepsy (IGE) indication expansion, as the FDA’s 180-day PMA review clock pause for the Nautilus supplement—triggered by follow-up questions during the mid-cycle review—introduces uncertainty regarding both timing and the potential label restrictions that may limit commercial uptake. While management anticipates a midyear determination, the agency’s focus on clarifying data interpretation and context around analyses, rather than just accepting the submitted evidence, suggests scrutiny over the robustness of the NAUTILUS trial’s primary endpoint, which did not meet statistical significance despite strong secondary outcomes like a 77% median reduction in generalized tonic-clonic seizures. This regulatory hesitation could delay approval beyond midyear, compress the revenue contribution window for FY26, and necessitate additional data generation or labeling concessions that reduce the addressable patient population or increase commercialization costs, undermining the bullish case for IGE-driven upside that is currently excluded from guidance but widely anticipated by investors.
The company’s operating leverage remains fragile and contingent on sustained commercial execution, as evidenced by Q1 FY26 non-GAAP operating expenses increasing 10% year-over-year to $21.5 million—driven by higher sales and marketing ($11.0 million, up from $9.6 million) and general and administrative costs ($4.0 million, up from $3.3 million)—while R&D spending declined only slightly ($6.5 million vs. $6.6 million), indicating limited efficiency gains in core innovation spend. Although operating expense growth stayed below the 20% revenue growth ex-DIXI, this leverage is dependent on continued productivity from recent commercial team investments, including sales representative additions and nurse navigator team expansion, which may not yield proportional returns if prescriber adoption or patient pipeline velocity fails to accelerate as expected. The reliance on these investments to drive growth introduces execution risk, particularly if macroeconomic headwinds or healthcare budget constraints slow capital allocation at Level 4 centers or delay community referral maturation, potentially undermining the assumed 21%-23% RNS growth trajectory and delaying profitability milestones.
Reimbursement dynamics for the RNS system present a structural challenge that could constrain long-term margin expansion and adoption rates, despite recent positive OPPS and APC mapping updates for device replacement. While management highlighted improved reimbursement alignment for replacements as a future tailwind, the first-time implant procedure remains on Medicare’s inpatient-only list, creating a significant barrier to outpatient adoption and limiting site-of-service flexibility, which is increasingly valued by hospitals and clinicians seeking to reduce costs and improve patient throughput. The lack of outpatient reimbursement for new implants constrains the total addressable market, particularly in community hospitals and ambulatory surgery centers, and may slow penetration beyond Level 4 epilepsy centers—a critical factor given management’s emphasis on community relationships as durable referral channels. Although NeuroPace advocates for policy change and cites broader payer openness to neuromodulation value, the absence of a clear pathway to outpatient APC status for first-time implants introduces uncertainty around scalability and could result in slower-than-expected utilization growth, especially if cost-containment pressures intensify in the U.S. healthcare system.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password